Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dimensional ETF Trust Dimensional US High Profitability ETF (NY:DUHP)

36.80 -0.01 (-0.03%)
Streaming Delayed Price Updated: 1:31 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dimensional ETF Trust Dimensional US High Profitability ETF

Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720
According to the Financial Times, the price for a month’s supply of the highest doses of the drug will rise from £122 to £330, an increase of 170%. 
Via Stocktwits
Topics Government World Trade
Apple Plans Tabletop Robot, Among Other AI Products, Says Report
Via Stocktwits
Topics Artificial Intelligence
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance
Texas Attorney General Ken Pax­ton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs. 
Via Stocktwits
Topics Fraud Law Enforcement Lawsuit
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant
Via Stocktwits
GM Secures Rare Earth Magnet Supply From Texas Partner Amid Push to Mitigate Tariffs
Noveon Magnetics said that it began delivering magnets to support GM's full-size SUVs and trucks in July. 
Via Stocktwits
Topics Earnings Economy World Trade
GM More Than Doubles EV Sales In July Ahead Of Federal Tax Credit Expiry: Chevrolet Equinox EV Leads Pack
Via Stocktwits
GM’s Mary Barra Highlights Efforts To Mitigate Tariff Impact After Q2 Earnings Take Hit: Retail Sees Levies Impact Consumer Spending
Via Stocktwits
Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here's What Investors Are Thinking
Via Stocktwits
Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Plan
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said. 
Via Stocktwits
Topics World Trade
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive
The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting... 
Via Stocktwits
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet
Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday. 
Via Stocktwits
Topics Workforce
GM EV Production To Be Guided By Consumer Demand, Says CFO As Federal Tax Credits Near Expiry
GM CFO said that the company’s recent $4 billion investment in U.S. manufacturing over the next two years gives it the necessary capabilities to produce both internal combustion engine and electric... 
Via Stocktwits
Topics Government
General Motors, LG Energy Solution JV To Upgrade Spring Hill Facility To Scale Low-Cost Battery Cell Making
Via Stocktwits
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. 
Via Stocktwits
Topics Product Recall
Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries
Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three years in countries supported by the Global Fund, at no profit to the company. 
Via Stocktwits
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less... 
Via Stocktwits
Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta
J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April. 
Via Stocktwits
Topics Government
GM Stock Rises As US Sales Jump 7% In Q2, Powered By Crossovers
Chevrolet, the company’s biggest brand, witnessed a 5.7% increase in sales in the quarter to 478,322 units, owing to a jump in sales of its Silverado and Equinox vehicles. 
Via Stocktwits
AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade
The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases. 
Via Stocktwits
Topics Intellectual Property
Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care
Jefferies termed the Supreme Court’s ruling an ‘incremental positive’ for Gilead that removes an overhang going into the launch for Yeztugo. 
Via Stocktwits
Trump HHS Pick Robert F. Kennedy Jr.'s Wealth Comes From Family, Law Practice, Oil, Bitcoin
Robert F. Kennedy Jr. owes portions of his wealth to his family name, law, cryptocurrency and oil. Here's a look at his wealth and income. 
Via Benzinga
Topics Government
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS